Headshot photo of Marcel E. Curlin, M.D.

Marcel E. Curlin, M.D.

  • Associate Professor of Medicine, Division of Infectious Diseases, School of Medicine
  • Medical Director, Occupational Health


Background: Dr. Curlin received an undergraduate degree from Amherst College in 1989, and a doctorate of medicine from the Oregon Health and Sciences University in 1995. After completing training in Internal Medicine (University of Utah, 1998) and Infectious Diseases (University of Washington, 2002), he remained at the University of Washington to pursue interests in molecular virology and HIV vaccine studies. In 2010, Dr. Curlin joined the US Centers for Disease Control and Prevention and served as the Chief of the HIV/STD laboratory sciences section in Bangkok, Thailand for four years. In 2015 Dr. Curlin returned to OHSU as faculty member in the Department of Medicine.

Service, research and teaching: Dr. Curlin is an active clinician on the Infectious Diseases Inpatient Consultation Service, leads the infectious diseases research program for OHSU Global SE Asia, serves as medical director of OHSU Occupational Health Department, and serves on the Institutional Biosafety Committee and the Faculty Senate. Dr Curlin pursues translational research in virology and immunology, and mentors undergraduate and graduate trainees in research and clinical medicine.

Education and training

  • Degrees

    • M.D., 1995, Oregon Health & Science University
  • Residency

    • Internal medicine, University of Utah, 1998
  • Fellowship

    • Infectious diseases, University of Washington, 2002
  • Certifications

    • American Board of Internal Medicine, 1998
    • American Board of Internal Medicine, Infectious Diseases, 2015

Memberships and associations:

  • International AIDS Society

Areas of interest

  • Dr. Curlin is a specialist in adult infectious diseases
  • Dr. Curlin has experience in both clinical and laboratory-based research in virology, HIV and immunology.


Elsevier pure profile

Selected publications

  • Previously infected vaccinees broadly neutralize SARS-CoV-2 variants. Leier HC, Bates TA, Lyski ZL, McBride SK, Lee DX, Coulter FJ, Goodman JR, Lu Z, Curlin ME, Messer WB, Tafesse FG. medRxiv [Preprint]. 2021 Apr 29


  • {{ pub.journalAssociation.journal.name.text[0].value }}